Last edition
News about "chronic obstructive pulmonary disease (COPD) "
GSK and Empirico Sign Licensing Deal for Respiratory Oligonucleotide
Oligonucleotide therapies, including siRNA, offer the potential to modulate gene expression and target diseases beyond the reach of traditional drugs. EMP-012 adds to GSK’s growing oligonucleotide pipeline across respiratory, immunology and inflammation, and infectious disease portfolios.
Chronic Obstructive Pulmonary Disease (COPD) | 29/10/2025 | By Dineshwori
Fosun Pharma Industrial has signed a global License Agreement with Expedition Therapeutics Inc., granting the US-based biotechnology company the rights to develop, manufacture, and commercialise its investigational respiratory drug XH-S004 in all regions worldwide, excluding the Chinese Mainland, Hong Kong SAR, and Macau SAR.
Chronic Obstructive Pulmonary Disease (COPD) | 13/08/2025 | By Dineshwori | 143
Merck to Acquire Verona Pharma for USD 10 Billion to Expand Cardio-Pulmonary Portfolio
Merck, through a subsidiary, will acquire Verona Pharma for USD 107 per American Depository Share (ADS), each of which represents eight shares of Verona Pharma, for a total transaction value of approximately USD 10 billion.
Chronic Obstructive Pulmonary Disease (COPD) | 10/07/2025 | By Dineshwori | 276
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy